

VERTEX PHARMA - KALYDECO + VX-809 Analysis – PhIII Should be Successful in CF patients with Homozygous ?F508 if....!

https://marketpublishers.com/r/VCC7C845C2AEN.html

Date: May 2012 Pages: 3 Price: US\$ 90.00 (Single User License) ID: VCC7C845C2AEN

Abstracts

Vertex (VRTX) evoked an uproar when it corrected the data of its KLAYDECO/VX-809 (CFTR Potentiator + Corrector) combo PhIIb interim data in homozygous ?F508 mutation Cystic Fibrosis (CF) pts this week. Our discussion with pulmonologists on the clinical significance of the data- 5 to 10% absolute improvement in lung function was positive. Based on our analysis and assumptions, we are optimistic that this combination can succeed in the PhIII study in CF pts with homozygous ?508 mutation, provided the PhIII trial design..... For more detail, please read our report released on 31th May, 2012 on Vertex titled "KALYDECO + VX-809 Analysis – PhIII Should be Successful in CF patients with Homozygous ?F508 if....!"



Contents

COMPANIES MENTIONED

VERTEX



I would like to order

Product name: VERTEX PHARMA - KALYDECO + VX-809 Analysis – PhIII Should be Successful in CF patients with Homozygous ?F508 if....!

Product link: https://marketpublishers.com/r/VCC7C845C2AEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/VCC7C845C2AEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



VERTEX PHARMA - KALYDECO + VX-809 Analysis - PhIII Should be Successful in CF patients with Homozygous ?F508 i...